CUMBERLAND PHARMACEUTICALS INC.

(CPIX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cumberland Pharmaceuticals Acquires US Rights to Sancuso Granisetron Patch From Kyowa Kirin

01/04/2022 | 01:09pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CUMBERLAND PHARMACEUTICALS INC. -0.93% 2.14 Delayed Quote.-53.75%
KIRIN HOLDINGS COMPANY, LIMITED -0.16% 1926.5 Delayed Quote.4.47%
KYOWA KIRIN CO. LTD. -1.37% 2734 Delayed Quote.-11.58%
All news about CUMBERLAND PHARMACEUTICALS INC.
05/13CUMBERLAND PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condi..
AQ
05/10CUMBERLAND : Q1 Earnings Snapshot
AQ
05/10Cumberland Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended Ma..
CI
05/10TRANSCRIPT : Cumberland Pharmaceuticals Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Posts Q1 Revenue $11.2M
MT
05/10Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q1 EPS $0.03
MT
05/10Cumberland Pharmaceuticals Reports 6% Revenue Growth
PR
05/09Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuti..
PR
05/09Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuti..
CI
05/03CUMBERLAND PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form..
AQ
More news
Financials (USD)
Sales 2021 36,0 M - -
Net income 2021 -3,51 M - -
Net cash 2021 11,0 M - -
P/E ratio 2021 -19,8x
Yield 2021 -
Capitalization 31,9 M 31,9 M -
EV / Sales 2020 0,98x
EV / Sales 2021 1,61x
Nbr of Employees 83
Free-Float 56,1%
Chart CUMBERLAND PHARMACEUTICALS INC.
Duration : Period :
Cumberland Pharmaceuticals Inc. Technical Analysis Chart | CPIX | US2307701092 | MarketScreener
Technical analysis trends CUMBERLAND PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
A. J. Kazimi Chairman & Chief Executive Officer
John M. Hamm Chief Financial & Accounting Officer
Leo B. Pavliv Chief Development Officer & EVP-Operations
James L. Herman Chief Compliance Officer & Senior Vice President
Gordon R. Bernard Independent Director